Protocol Status: PUBLISHED
Protocol:
Version: 2026.01
Effective Date:
Last Reviewed:
Medical Director Approval:
Clinical Note: This content reflects current GCEMS clinical guidelines as of the dates listed above. If content appears inconsistent with current policy, use the most recent approved guideline and notify leadership for correction.

Atropine

 

Indications:

 

  • Anticholinergic drug used in bradycardias
  • Organophosphate poisoning
  • Pediatric:
    • Symptomatic bradycardia secondary to AV block or vagal activity 2nd line after Epinephrine for bradycardia due to poor perfusion or hypotension.

 

Contraindications:

 

  • Tachycardia
  • Hypertension (rule out head injury first)

 

Side Effects:

 

  • tachycardia
  • dry mouth
  • thirst
  • flushing of skin
  • blurred vision
  • headache
  • pupillary dilation
  • urine retention

 

Adult Dosage:

 

  • Bradycardia

 

    • 1 mg IV administration; repeat Q 3-5 minutes to a total dose of 3 mg

 

  • Organophosphate Poisoning:

 

    • To block parasympathetic response:

 

      • 1 - 2 mg; IV dose repeated Q 5 minutes until a decrease in secretions are observed or to total dose of 6 mg.

 

Pediatric:

 

  • Bradycardia

 

    • 0.02 mg/kg (0.2 ml/kg) IV, Minimum 0.1 mg,
    • Maximum single dose 0.5 mg child; 1 mg adolescent.
    • May be repeated once

 

  • Organophosphate Poisoning:

 

    • To block parasympathetic response:

 

      • Children: 0.05 to 0.1 mg/kg Loading dose. Adolescents: 2 mg
      • Repeat every 10 – 15 minutes until rales and bronchial secretions resolved.